NanoCarrier's core technology, micellar nanoparticles technology, was proposed and has been researched by Professor Kazunori Kataoka of University of Tokyo, Professor Teruo Okano of Tokyo Women's Medical University and Associate professor Masayuki Yokoyama of the Jikei University.

Rapid DNA Sequencing and Screening Analysis for Whole Genomes, mRNA, PCR, & cDNA. Polymorphism Analysis & Sage™ Research for Pharmacogenomics, Comparative Genomics, & Genotyping.

At 7TM Pharma we focus on developing our pipeline of clinical assets forward with a primary therapeutic focus in obesity, related metabolic diseases and gastrointestinal diseases. These are areas with obvious unmet medicinal needs.

ABC's focus on operational excellence is evidenced by continuous process improvement, performance monitoring and metrics reporting--rigorous self-evaluation you don't always see in a contract research lab, no matter what their size.

Abgent develops powerful tools to profile posttranslational modifications related to cellular function and disease. Abgent antibodies target protein kinases, phosphatases, methyl and acetyl transferases, ubiquitin and SUMO, glycosylases and other protein modification enzymes.

AbOrygen develops the next generation of bioinformatics software with powerful new features that simplify and improve the research work of life scientists worldwide.

ACADIA is a leading biopharmaceutical company developing treatments for central nervous system disorders, Parkinson´s disease and schizophrenia. ACP-103 and ACP-104 in clinical development.

Based on its analysis of the integrated insilico drug discovery solutions market, Frost & Sullivan recognized Accelrys, Inc., with the 2010 North America Frost & Sullivan Award for New Product Innovation of the Year.

ActivX is an emerging biopharmaceutical company that discovers and develops highly selective, best in class, small molecule drugs for major unmet medical needs.